Is wood the next advanced material?
Scientists at the University of Maryland reported last week that they’ve discovered a way to treat wood to make it 12 times stronger than natural wood and 10 times tougher. According to Liangbing Hu, one the lead researchers in the paper published in Nature, their wood is so strong and durable that it can compete with steel, titanium alloys, and even carbon fiber–but at an infinitely much lower price point.
Brown Advisory—an investment and strategic advisory firm committed to making a material and positive difference in the lives of its clients—is excited to join forces with network-driven venture capital firm, NextGen Venture Partners (“NextGen”). On Feb. 22, 2018, the NextGen team will officially join their new Brown Advisory colleagues in offices across the United States.
SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, and ABL Europe, an ABL, Inc. company providing dedicated viral vector GMP services for gene therapy, oncolytic products and vaccines for all stages of clinical supply, have expanded their strategic manufacturing collaboration. Under the current agreement, ABL is currently manufacturing Pexa-Vec (formerly JX-594) for SillaJen’s multinational, randomized Phase 3, open-label study of Pexa-Vec in patients with advanced liver cancer. Under the expanded agreement, ABL will also provide development, manufacturing & QC release testing services for SillaJen’s pipeline product, JX-970.
The ability for cancer cells to develop resistance to chemotherapy drugs – known as multidrug resistance – remains a leading cause for tumor recurrence and cancer metastasis, but recent findings offer hope that oncologists could one day direct cancer cells to “turn off” their resistance capabilities.
In the last six months, Personal Genome Diagnostics (PGDx) raised a $75 million series B, Harpoon Medical sold for $100 million and Sunayu acquired Fractal Technology. Which Baltimore startup is next?
Lonza Pharma & Biotech and Denali Therapeutics (NASDAQ: DNLI) announced today an exclusive strategic partnership on Denali’s biologic pipeline products for neurodegenerative diseases. The agreement covers all stages of the development and manufacturing,
Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, announced that updated safety and efficacy data from the ongoing Phase 2a clinical trial of RX-3117 in advanced urothelial (bladder) cancer were presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting on February 9, 2018.
The University System of Maryland Board of Regents voted on Friday to approve the construction of a new engineering facility on the University of Maryland’s campus.
Shepherd University has created a new nonprofit organization with a mission of helping facilitate research, innovation, and entrepreneurship. On January 24, the Internal Revenue Service approved the Shepherd Entrepreneurship and Research Corporation’s (SERC) status as a 501(c)(3).
By StartUp Health’s reckoning, New York City was the second most active city for health tech dealflow in 2017 with $1 billion invested across 63 deals. San Francisco had nearly twice the number of deals and more than three times the amount, but the closest to New York was Boston with 29.
